161Tb Radiopharmaceutical Therapy as a Treatment for RANKL-Positive Multiple Myeloma.
Findings support 161Tb as a next-generation theranostic radionuclide for RANKL-positive malignancies and provide a strong rationale for clinical translation, highlighting the value of repurposing a clinically established antibody for radiopharmaceutical therapy.